Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4SWQA)

• Drug Name: Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73347134
  TTD Drug ID: DM4SWQA

Molecule-Related Drug Atlas

Drug(s) Targeting Neuropeptide Y receptor type 2 (NPY2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[2]
TM30338	DMXNQLU	Obesity	5B81	Discontinued in Phase 2	[3]
PYY3-36	DMTGFV6	Obesity	5B81	Discontinued in Phase 2	[4]
AC-162352	DME98LV	Obesity	5B81	Discontinued in Phase 1	[4]
BMS-192548	DMHAWBR	Obesity	5B81	Preclinical	[4]
CIN-110	DMYMZQW	Obesity	5B81	Preclinical	[5]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	DMKH8PF	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	DM9XK05	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Neuropeptide Y receptor type 4 (NPY4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TM30338	DMXNQLU	Obesity	5B81	Discontinued in Phase 2	[3]
TM30339	DMW7LQT	Schizophrenia	6A20	Discontinued in Phase 2	[6]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	DMKH8PF	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	DM9XK05	Discovery agent	N.A.	Investigative	[1]
Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMVWM75	Discovery agent	N.A.	Investigative	[1]
[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMWFGBC	Discovery agent	N.A.	Investigative	[1]
[125I]GR231118	DMFWE4H	Discovery agent	N.A.	Investigative	[7]
PD-4074	DM4BDEY	Diabetic complication	5A2Y	Investigative	[8]

Drug(s) Targeting Neuropeptide Y receptor type 1 (NPY1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[9]
H-409/22	DMYJ9CF	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[10]
PD-160170	DMB9Z4C	Heart disease	BA41-BA42	Preclinical	[4]
GI-264879A	DM25N8B	Obesity	5B81	Preclinical	[4]
SR 120819A	DMETDFM	Eating disorder	6B82	Terminated	[11]
BIBP 3226	DMYBR9D	Hypertension	BA00-BA04	Terminated	[12]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[13]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	DMKH8PF	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuropeptide Y receptor type 1 (NPY1R)	TTRK9JT	NPY1R_HUMAN	Inhibitor	[1]
Neuropeptide Y receptor type 2 (NPY2R)	TTJ6WK9	NPY2R_HUMAN	Inhibitor	[1]
Neuropeptide Y receptor type 4 (NPY4R)	TTW4N16	NPY4R_HUMAN	Inhibitor	[1]

References

• [1] Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
• [2] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [3] Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
• [4] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [5] Clinical pipeline report, company report or official report of CinFina Pharma
• [6] Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev. 2007 Oct;28(6):664-84.
• [7] [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307).
• [9] 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
• [10] In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
• [11] SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
• [13] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.